Login
Vericel NASDAQ: VCEL
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
| Name | Vericel |
| Ticker | VCEL |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 18.92 |
| 52W Low/High | 7.25 / 19.22 |
| Market cap | 853 M |
| 1Y Total Return |
18.55%
Strong |
| 1Y Volatility |
66.58%
More Risk |
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
Details
| Ticker | VCEL |
| Name | Vericel |
| ISIN | US92346J1088 |
| CUSIP | 92346J108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 9/22/20
| Close Price | 18.92 |
| 52W Low/High | 7.25 / 19.22 |
| Market cap | 853 M |
| 1Y Total Return |
18.55%
Strong |
| 1Y Volatility |
66.58%
More Risk |
| Beta | 1.26 |
| PE (trailing) |
1,892.00
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 0.0% |
| Cash from Op. / Cur. Liabilities | 0.70 |
| Diluted Earnings / Share | 0.01 |
| ROE | - |
| ROIC | 0.0% |
| Price / Revenue | 7.3 |
| Price / Book | 7.9 |
| Price / CF | 67.2 |
| Current Ratio | 6.4 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.25 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
117
|
102
|
75
|
54
|
54
|
49
|
|
| Gross Profit |
78
|
67
|
44
|
25
|
26
|
24
|
|
| R&D |
13
|
30
|
14
|
14
|
19
|
21
|
|
| EBITDA |
4
|
-15
|
-14
|
-22
|
-14
|
-15
|
|
| Operating Income |
-1
|
-19
|
-11
|
-24
|
-17
|
-17
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
45
|
44
|
38
|
33
|
23
|
24
|
|
| EPS exc. Extra |
0.01
|
-0.40
|
-0.47
|
-1.10
|
-1.00
|
-0.58
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
147
|
126
|
122
|
37
|
29
|
41
|
|
| Cash, Eq & Invt ShortTerm |
81
|
66
|
95
|
14
|
10
|
20
|
|
| Total Current Assets |
116
|
94
|
118
|
33
|
22
|
34
|
|
| Total Non-Current Assets |
31
|
32
|
5
|
3
|
7
|
8
|
|
| Intangibles |
0
|
0
|
0
|
0
|
3
|
3
|
|
| Total Liabilities |
39
|
37
|
32
|
23
|
12
|
11
|
|
| Total Current Liabilities |
18
|
13
|
15
|
13
|
11
|
11
|
|
| Long Term Debt |
21
|
25
|
16
|
10
|
1
|
0
|
|
| Shareholder equity |
108
|
89
|
91
|
14
|
17
|
30
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
13
|
-14
|
-9
|
-22
|
-11
|
-23
|
|
| Depreciation |
4
|
2
|
2
|
2
|
2
|
1
|
|
| Cash from Investing |
25
|
-54
|
-2
|
-1
|
-2
|
-5
|
|
| Capex |
3
|
3
|
2
|
1
|
2
|
2
|
|
| Cash from Financing |
4
|
-13
|
93
|
27
|
3
|
41
|
|
| Stock Issued |
5
|
5
|
86
|
19
|
0
|
41
|
|
| Debt (LT) Issued |
0
|
-18
|
7
|
8
|
2
|
0
|
|
| Free Cash Flow |
-2
|
-31
|
-22
|
-29
|
-16
|
-37
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.4
|
7.5
|
7.7
|
2.6
|
1.9
|
3.1
|
|
| Financial Leverage D/E |
0.25
|
0.31
|
0.19
|
0.73
|
0.14
|
0.00
|
|
| Return on Capital Avg |
0.0%
|
-31.6%
|
-148.5%
|
-273.2%
|
-174.7%
|
-571.2%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available